PT-141 10mg

Melanocortin receptor agonist (MC3R/MC4R) — synthetic cyclic heptapeptide Structural derivative of α-MSH analog Melanotan II with distinct receptor selectivity Research-grade · CAS 189691-06-3 For in vitro melanocortin receptor research only

$39.99 In stock

SSL 256-bit Secure Checkout

Same-day dispatch on orders before 12:00 PM ET, Mon–Fri. Discreet, plain packaging.

View this compound’s Certificate of Analysis →

For laboratory research use only. Not for human or veterinary consumption. SKU P41.

Overview

Product details.

PT-141 10mg — Bremelanotide

PT-141 began its life as a derivative of Melanotan II but ended up somewhere unexpected. By removing the C-terminal amide from its parent compound, researchers created a cyclic heptapeptide with a shifted melanocortin receptor selectivity profile — one that preferentially engages MC3R and MC4R subtypes in hypothalamic regions rather than acting peripherally. The result, documented by Pfaus et al. in PNAS (2004), is a compound that triggers downstream dopamine release through central nervous system melanocortin pathways (PubMed 15226502).

Research-Grade Compounds

Manufactured to research-grade standards for laboratory research use only.

Discreet Shipping

Every order ships in plain, protective packaging.

In-House Fulfillment

Orders are inspected, packed, and shipped directly by the Heritage Labs team.

Specifications

Sequence	Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular Formula	C₅₀H₆₈N₁₄O₁₀
Molecular Weight	1025.18 g/mol
CAS Number	189691-06-3
Classification	MC3R/MC4R melanocortin receptor agonist
Form	Lyophilized powder
Quantity	10mg per vial

The melanocortin angle

MC3R sits primarily in the hypothalamus and is associated with energy homeostasis research. MC4R is involved in appetite regulation, energy expenditure, and reproductive function in preclinical models. PT-141 hits both. Thurston et al. used fMRI to document amplified cerebellar/motor area activity and amygdala-insula functional connectivity during controlled stimulus paradigms in MC4R agonism studies (J Clinical Investigation, 2022; PubMed 36194485).

Structurally, the compound features a norleucine substitution at the N-terminus and a constrained cyclic core via a lactam bridge — giving it defined conformational stability and consistent receptor-binding characteristics in analytical work.

PT-141 vs Melanotan II

Same cyclic core, different receptor profile. Removing the C-terminal amide changes how the peptide interacts with MC3R and MC4R in competitive binding assays. PT-141 research has concentrated on central melanocortin pathway activation, while Melanotan II research covers a broader receptor spectrum.

Frequently paired with

Selank 5mg — Complementary neuropeptide research.

Quality and testing

Every Heritage Labs compound is manufactured to research-grade standards and shipped in protective packaging.

Storage

Lyophilized: -20°C
Reconstituted: 2-8°C, use within 30 days
Protection: Shield from light and moisture; avoid freeze-thaw cycles

References

Pfaus JG, et al. PNAS. 2004;101(27):10201-10204. PubMed 15226502
Mulhall JP, et al. J Urology. 2001;166(4):628-634.
Shabsigh R, et al. J Sexual Medicine. 2006;3(4):628-636.
Thurston L, et al. J Clinical Investigation. 2022;132(19):e152341. PubMed 36194485
Haskell-Luevano C, et al. Nature. 2001;410:1139-1143.

For laboratory research use only. Not for human or veterinary use.

For laboratory research use only. Not for human or veterinary use. This product is not a drug or supplement and is not intended to diagnose, treat, cure, or prevent any disease.

FDA Disclaimer. All products are for research use only (RUO) as defined by the FDA — not for diagnostic, human, or veterinary use. These products have not been evaluated and have not been approved by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

Heritage Labs is a chemical supplier providing products strictly for laboratory research, analytical, and in-vitro purposes; it is not a compounding pharmacy or compounding facility under Section 503A, nor an outsourcing facility under Section 503B, of the Federal Food, Drug, and Cosmetic Act.